<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:43:21Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9255975" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9255975</identifier>
        <datestamp>2022-07-06</datestamp>
        <setSpec>oncologist</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Oncologist</journal-id>
              <journal-id journal-id-type="iso-abbrev">Oncologist</journal-id>
              <journal-id journal-id-type="publisher-id">oncolo</journal-id>
              <journal-title-group>
                <journal-title>The Oncologist</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1083-7159</issn>
              <issn pub-type="epub">1549-490X</issn>
              <publisher>
                <publisher-name>Oxford University Press</publisher-name>
                <publisher-loc>US</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9255975</article-id>
              <article-id pub-id-type="pmcid">PMC9255975</article-id>
              <article-id pub-id-type="pmc-uid">9255975</article-id>
              <article-id pub-id-type="pmid">35285484</article-id>
              <article-id pub-id-type="pmid">35285484</article-id>
              <article-id pub-id-type="doi">10.1093/oncolo/oyac002</article-id>
              <article-id pub-id-type="publisher-id">oyac002</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Clinical Trial Results</subject>
                </subj-group>
                <subj-group subj-group-type="category-taxonomy-collection">
                  <subject>AcademicSubjects/MED00010</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>N064A (Alliance): Phase II Study of Panitumumab, Chemotherapy, and External Beam Radiation in Patients with Locally Advanced Pancreatic Adenocarcinoma</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8460-1257</contrib-id>
                  <name>
                    <surname>Halfdanarson</surname>
                    <given-names>Thorvardur R</given-names>
                  </name>
                  <aff><institution>Division of Medical Oncology, Mayo Clinic</institution>, <addr-line>Rochester, MN</addr-line>, <country country="US">USA</country></aff>
                  <xref rid="c1" ref-type="corresp"/>
                  <!--halfdanarson.thorvardur@mayo.edu-->
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Foster</surname>
                    <given-names>Nathan R</given-names>
                  </name>
                  <aff><institution>Alliance Statistics and Data Center, Mayo Clinic</institution>, <addr-line>Rochester, MN</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kim</surname>
                    <given-names>George P</given-names>
                  </name>
                  <aff><institution>George Washington University Cancer Center</institution>, <addr-line>Washington, DC</addr-line>, <country country="US">USA</country></aff>
                  <xref rid="fn-0001" ref-type="author-notes"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Haddock</surname>
                    <given-names>Michael G</given-names>
                  </name>
                  <aff><institution>Department of Radiation Oncology, Mayo Clinic</institution>, <addr-line>Rochester, MN</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dakhil</surname>
                    <given-names>Shaker R</given-names>
                  </name>
                  <aff><institution>Cancer Center of Kansas</institution>, <addr-line>Wichita, KS</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Behrens</surname>
                    <given-names>Robert J</given-names>
                  </name>
                  <aff><institution>Mission Cancer + Blood</institution>, <addr-line>Des Moines, IA</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Alberts</surname>
                    <given-names>Steven R</given-names>
                  </name>
                  <aff><institution>Division of Medical Oncology, Mayo Clinic</institution>, <addr-line>Rochester, MN</addr-line>, <country country="US">USA</country></aff>
                </contrib>
              </contrib-group>
              <author-notes>
                <corresp id="c1">Corresponding author: Thorvardur R. Halfdanarson, MD, Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Tel: <phone>+1-319-400-2181</phone>; Email: <email>halfdanarson.thorvardur@mayo.edu</email></corresp>
                <fn id="fn-0001">
                  <p>Principal Investigator: George P. Kim</p>
                </fn>
              </author-notes>
              <pub-date pub-type="collection">
                <month>7</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="epub" iso-8601-date="2022-03-14">
                <day>14</day>
                <month>3</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>14</day>
                <month>3</month>
                <year>2022</year>
              </pub-date>
              <volume>27</volume>
              <issue>7</issue>
              <fpage>534</fpage>
              <lpage>e546</lpage>
              <history>
                <date date-type="received">
                  <day>10</day>
                  <month>9</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>20</day>
                  <month>12</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Â© The Author(s) 2022. Published by Oxford University Press. The data published online to support this summary are the property of the authors. Please contact the authors about reuse rights of the original data.</copyright-statement>
                <copyright-year>2022</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.The data published online to support this summary are the property of the authors. Please contact the authors about reuse rights of the original data.</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="oyac002.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="s100">
                  <title>Background</title>
                  <p>This North Central Cancer Treatment Group (NCCTG) N064A (Alliance) phase II trial evaluated upfront chemoradiotherapy incorporating the EGFR inhibitor panitumumab, followed by gemcitabine and panitumumab for unresectable, non-metastatic pancreatic cancer.</p>
                </sec>
                <sec id="s101">
                  <title>Methods</title>
                  <p>The treatment consisted of fluoropyrimidine and panitumumab given concurrently with radiotherapy followed by gemcitabine and panitumumab for 3 cycles followed by maintenance panitumumab. The primary endpoint was the 12-month overall survival (OS) rate and secondary endpoints included confirmed response rate (RR), OS, progression-free survival (PFS), and adverse events. Enrollment of 50 patients was planned and the study fully accrued.</p>
                </sec>
                <sec id="s102">
                  <title>Results</title>
                  <p>Fifty-two patients were enrolled, but only 51 were treated and included in the analysis. The median age of patients was 65 years and 54.9% were women. Twenty-two patients received at least 1 cycle of systemic therapy following radiotherapy, but 29 patients received chemoradiotherapy only without receiving subsequent chemotherapy after completion of chemoradiotherapy. The overall RR was 5.9% (95% CI: 1.2%-16.2%). The 12-month OS rate was 50% (95% CI: 38%-67%) which fell short of the per-protocol goal for success (51.1%). The median PFS was 7.4 months (95% CI: 4.5-8.6) and the median OS was 12.1 months (95% CI 7.9-15.9). Grade 3 or higher adverse events were reported by 88%.</p>
                </sec>
                <sec id="s103">
                  <title>Conclusion</title>
                  <p>The combination of panitumumab, chemotherapy, and external beam radiation therapy was associated with very high rates of grades 3-4 toxicities and survival results did not meet the trialâs goal for success. This regimen is not recommended for further study (ClinicalTrials.gov Identifier NCT00601627).</p>
                </sec>
              </abstract>
              <abstract abstract-type="teaser">
                <p>This article describes results of a phase II trial by the North Central Cancer Treatment Group (NCCTG) that evaluated upfront chemoradiotherapy incorporating the EGFR inhibitor panitumumab followed by gemcitabine and panitumumab for non-metastatic pancreatic cancer.</p>
              </abstract>
              <kwd-group>
                <kwd>pancreatic adenocarcinoma</kwd>
                <kwd>panitumumab</kwd>
                <kwd>radiotherapy</kwd>
                <kwd>locally advanced</kwd>
              </kwd-group>
              <funding-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>Alliance for Clinical Trials in Oncology</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <counts>
                <page-count count="6"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <boxed-text position="float" id="B1">
              <caption>
                <title>Lessons Learned</title>
              </caption>
              <list list-type="bullet">
                <list-item>
                  <p>The combination of panitumumab, cytotoxic chemotherapy, and external beam radiation therapy is associated with substantial toxicity and should not be used in clinical practice and is not recommended for further study.</p>
                </list-item>
                <list-item>
                  <p>Progression-free survival and OS appear shorter than in studies utilizing upfront chemotherapy followed by chemoradiotherapy for selected patients.</p>
                </list-item>
              </list>
            </boxed-text>
            <sec id="s1">
              <title>Discussion</title>
              <p>Locally advanced and unresectable pancreatic cancer constitutes more than 50% of newly diagnosed pancreatic adenocarcinoma. Overall survival is poor and median OS is generally &lt;18 months.<sup><xref rid="CIT0001" ref-type="bibr">1</xref>,<xref rid="CIT0002" ref-type="bibr">2</xref></sup> The optimal treatment of patients with unresectable pancreatic adenocarcinoma is not known, but patients are increasingly treated initially with systemic chemotherapy alone, with radiotherapy reserved for selected patients who do not have progressive disease after several months of chemotherapy.</p>
              <p>The NCCTG N064A (Alliance) was a single arm phase II trial in patients with locally advanced and unresectable pancreatic adenocarcinoma. After written consent and registration, participants received radiotherapy with fluoropyrimidine as a radiosensitizer concurrent with panitumumab. The choice of radiosensitizing fluoropyrimidine, either 5-fluorouracil or capecitabine, was at the physicianâs discretion. North Central Cancer Treatment Group is now part of the Alliance for Clinical Trials in Oncology.</p>
              <p>Overall survival at 12 months, the primary endpoint of the trial, was 50% and fell just short of the pre-defined, per-protocol goal for success (51.1%). Twenty-two patients received at least 1 cycle of systemic therapy following radiotherapy. However, 29 patients received chemoradiotherapy alone without chemotherapy after completion of chemoradiotherapy, suggesting that the majority of patients received suboptimal therapy by current standards. Grade 3 or higher adverse events (at least possibly related to treatment) were reported by 88% of participants (<xref rid="T1" ref-type="table">Table 1</xref>).</p>
              <table-wrap position="float" id="T1">
                <label>Table 1.</label>
                <caption>
                  <p>Adverse events (grade 3 or higher).</p>
                </caption>
                <table frame="hsides" rules="groups" width="100%" border="1">
                  <colgroup span="1">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                  </colgroup>
                  <thead>
                    <tr>
                      <th align="left" rowspan="1" colspan="1">Event</th>
                      <th align="left" rowspan="1" colspan="1">All AEs, %</th>
                      <th align="left" rowspan="1" colspan="1">AEs related to therapy<xref rid="T1Fn1" ref-type="table-fn"><sup>a</sup></xref>, %</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Overall AEs</td>
                      <td align="left" rowspan="1" colspan="1">92.2</td>
                      <td align="left" rowspan="1" colspan="1">88.2</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Hematologic</td>
                      <td align="left" rowspan="1" colspan="1">41.2</td>
                      <td align="left" rowspan="1" colspan="1">41.2</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">âAnemia</td>
                      <td align="left" rowspan="1" colspan="1">10</td>
                      <td align="left" rowspan="1" colspan="1">10</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">âNeutropenia</td>
                      <td align="left" rowspan="1" colspan="1">14</td>
                      <td align="left" rowspan="1" colspan="1">14</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">âThrombocytopenia</td>
                      <td align="left" rowspan="1" colspan="1">6</td>
                      <td align="left" rowspan="1" colspan="1">6</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">âThrombosis</td>
                      <td align="left" rowspan="1" colspan="1">10</td>
                      <td align="left" rowspan="1" colspan="1">6</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Non-hematologic</td>
                      <td align="left" rowspan="1" colspan="1">88.2</td>
                      <td align="left" rowspan="1" colspan="1">84.3</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">âAnorexia</td>
                      <td align="left" rowspan="1" colspan="1">27</td>
                      <td align="left" rowspan="1" colspan="1">25</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">âDehydration</td>
                      <td align="left" rowspan="1" colspan="1">25</td>
                      <td align="left" rowspan="1" colspan="1">24</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">âDiarrhea</td>
                      <td align="left" rowspan="1" colspan="1">20</td>
                      <td align="left" rowspan="1" colspan="1">16</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">âFatigue</td>
                      <td align="left" rowspan="1" colspan="1">37</td>
                      <td align="left" rowspan="1" colspan="1">33</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">âHypotension</td>
                      <td align="left" rowspan="1" colspan="1">6</td>
                      <td align="left" rowspan="1" colspan="1">6</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">âNausea</td>
                      <td align="left" rowspan="1" colspan="1">35</td>
                      <td align="left" rowspan="1" colspan="1">29</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">âRash</td>
                      <td align="left" rowspan="1" colspan="1">16</td>
                      <td align="left" rowspan="1" colspan="1">16</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">âVomiting</td>
                      <td align="left" rowspan="1" colspan="1">22</td>
                      <td align="left" rowspan="1" colspan="1">16</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="T1Fn1">
                    <p>Adverse events at least possibly related to treatment.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>The observed survival, which compares unfavorably with more recently reported results, and the very high rates of significant adverse events support that this regimen should not be used in practice or recommended for further study.</p>
            </sec>
            <sec id="s2">
              <title>Trial Information</title>
              <table-wrap position="float" id="T1001">
                <table frame="hsides" rules="groups" width="100%" border="1">
                  <colgroup span="1">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                  </colgroup>
                  <tbody>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Disease</td>
                      <td align="left" rowspan="1" colspan="1">pancreatic cancer</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Stage of disease/treatment</td>
                      <td align="left" rowspan="1" colspan="1">metastatic/advanced</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Prior therapy</td>
                      <td align="left" rowspan="1" colspan="1">none</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Type of study</td>
                      <td align="left" rowspan="1" colspan="1">phase II, single arm</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Primary endpoint</td>
                      <td align="left" rowspan="1" colspan="1">12-month OS</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Secondary endpoints</td>
                      <td align="left" rowspan="1" colspan="1">overall RR, OS, PFS, toxicity</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Additional details of endpoints or study design</td>
                      <td align="left" rowspan="1" colspan="1">The study was open to accrual from June 19, 2009 to August 6, 2010. The study was permanently closed on August 6, 2010. The primary endpoint was the 12-month OS rate and secondary endpoints included RR, OS, PFS, and adverse events. The study had 91% power to detect a 12-month OS rate of 60%, with a 9% significance level when the true 12-month OS rate was 40%. An observed 12-month OS rate of 51.1% was needed for success. For time-to-event data (OS, PFS), a Kaplan-Meier analysis was performed, where medians and 95% confidence intervals were reported. For categorical data (ie, response, adverse events), the frequencies and percentages were reported, including 95% confidence intervals, as needed.</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Investigatorâs analysis</td>
                      <td align="left" rowspan="1" colspan="1">poorly tolerated/not feasible</td>
                    </tr>
                  </tbody>
                </table>
              </table-wrap>
            </sec>
            <sec id="s3">
              <title>Drug Information</title>
              <table-wrap position="float" id="T1002">
                <table frame="hsides" rules="groups" width="100%" border="1">
                  <colgroup span="1">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                  </colgroup>
                  <thead>
                    <tr>
                      <th align="left" rowspan="1" colspan="1">Generic/working name</th>
                      <th align="left" rowspan="1" colspan="1">5-Fluorouracil</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Drug type</td>
                      <td align="left" rowspan="1" colspan="1">Cytotoxic</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Drug class</td>
                      <td align="left" rowspan="1" colspan="1">Antimetabolite</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Dose</td>
                      <td align="left" rowspan="1" colspan="1">225Â mg/m<sup>2</sup></td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Route</td>
                      <td align="left" rowspan="1" colspan="1">Continuous intravenous infusion (CIV)</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Schedule of administration</td>
                      <td align="left" rowspan="1" colspan="1">Upfront chemoradiotherapy</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">Panitumumab: 6Â mg/kg on days 1, 15, and 29 of radiotherapy</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">5-fluorouracil (39 patients): 225Â mg/m<sup>2</sup> per day as continuous infusion during radiotherapy OR Capecitabine (12 patients): 825Â mg/m<sup>2</sup> PO twice daily during radiotherapy</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">Post-radiotherapy chemotherapy</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">Gemcitabine: 1000Â mg/m<sup>2</sup> on days 1, 8, and 15 on a 28-day cycle</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">Panitumumab: 6Â mg/kg i.v. on days 1 and 15 on a 28-day cycle</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">Maintenance therapy</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">Panitumumab: 6Â mg/kg i.v. on days 1 and 15 on a 28-day cycle</td>
                    </tr>
                  </tbody>
                </table>
                <table frame="hsides" rules="groups" width="100%" border="1">
                  <thead>
                    <tr>
                      <th align="left" rowspan="1" colspan="1">Generic/working name</th>
                      <th align="left" rowspan="1" colspan="1">Capecitabine</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Drug type</td>
                      <td align="left" rowspan="1" colspan="1">Cytotoxic</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Drug class</td>
                      <td align="left" rowspan="1" colspan="1">Antimetabolite</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Dose</td>
                      <td align="left" rowspan="1" colspan="1">825Â mg/m<sup>2</sup></td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Route</td>
                      <td align="left" rowspan="1" colspan="1">Oral (p.o.)</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Schedule of administration</td>
                      <td align="left" rowspan="1" colspan="1">Upfront chemoradiotherapy</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">Panitumumab: 6Â mg/kg on days 1, 15, and 29 of radiotherapy</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">5-Fluorouracil (39 patients): 225Â mg/m<sup>2</sup> per day as continuous infusion during radiotherapy OR Capecitabine (12 patients): 825Â mg/m<sup>2</sup> PO twice daily during radiotherapy</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">Post-radiotherapy chemotherapy</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">Gemcitabine: 1000Â mg/m<sup>2</sup> on days 1, 8, and 15 on a 28-day cycle</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">Panitumumab: 6Â mg/kg i.v. on days 1 and 15 on a 28-day cycle</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">Maintenance therapy</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">Panitumumab: 6Â mg/kg IV on days 1 and 15 on a 28-day cycle</td>
                    </tr>
                  </tbody>
                </table>
                <table frame="hsides" rules="groups" width="100%" border="1">
                  <thead>
                    <tr>
                      <th align="left" rowspan="1" colspan="1">Generic/working name</th>
                      <th align="left" rowspan="1" colspan="1">Panitumumab</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Drug type</td>
                      <td align="left" rowspan="1" colspan="1">Antibody</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Drug class</td>
                      <td align="left" rowspan="1" colspan="1">EGFR</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Dose</td>
                      <td align="left" rowspan="1" colspan="1">6Â mg/kg</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Route</td>
                      <td align="left" rowspan="1" colspan="1">i.v.</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Schedule of administration</td>
                      <td align="left" rowspan="1" colspan="1">Upfront chemoradiotherapy</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">Panitumumab: 6Â mg/kg on days 1, 15, and 29 of radiotherapy</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">5-fluorouracil (39 patients): 225Â mg/m<sup>2</sup> per day as continuous infusion during radiotherapy OR Capecitabine (12 patients): 825Â mg/m<sup>2</sup> PO twice daily during radiotherap</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">Post-radiotherapy chemotherapy</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">Gemcitabine: 1000Â mg/m<sup>2</sup> on days 1, 8, and 15 on a 28-day cycle</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">Panitumumab: 6Â mg/kg i.v. on days 1 and 15 on a 28-day cycle</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">Maintenance therapy</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">Panitumumab: 6Â mg/kg i.v. on days 1 and 15 on a 28-day cycle</td>
                    </tr>
                  </tbody>
                </table>
                <table frame="hsides" rules="groups" width="100%" border="1">
                  <thead>
                    <tr>
                      <th align="left" rowspan="1" colspan="1">Generic/working name</th>
                      <th align="left" rowspan="1" colspan="1">Gemcitabine</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Drug type</td>
                      <td align="left" rowspan="1" colspan="1">Cytotoxic</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Drug class</td>
                      <td align="left" rowspan="1" colspan="1">Antimetabolite</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Dose</td>
                      <td align="left" rowspan="1" colspan="1">1000Â mg/mÂ²</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Route</td>
                      <td align="left" rowspan="1" colspan="1">i.v.</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Schedule of administration</td>
                      <td align="left" rowspan="1" colspan="1">Upfront chemoradiotherapy</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">Panitumumab: 6Â mg/kg on days 1, 15, and 29 of radiotherapy</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">5-Fluorouracil (39 patients): 225Â mg/m<sup>2</sup> per day as continuous infusion during radiotherapy OR Capecitabine (12 patients): 825Â mg/m<sup>2</sup> PO twice daily during radiotherapy</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">Post-radiotherapy chemotherapy</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">Gemcitabine: 1000Â mg/m<sup>2</sup> on days 1, 8, and 15 on a 28-day cycle</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">Panitumumab: 6Â mg/kg i.v. on days 1 and 15 on a 28-day cycle</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">Maintenance therapy</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">Panitumumab: 6Â mg/kg i.v. on days 1 and 15 on a 28-day cycle</td>
                    </tr>
                  </tbody>
                </table>
              </table-wrap>
            </sec>
            <sec id="s4">
              <title>Patient Characteristics</title>
              <table-wrap position="float" id="T1003">
                <table frame="hsides" rules="groups" width="100%" border="1">
                  <colgroup span="1">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                  </colgroup>
                  <tbody>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Number of patients, male</td>
                      <td align="left" rowspan="1" colspan="1">23</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Number of patients, female</td>
                      <td align="left" rowspan="1" colspan="1">28</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Stage</td>
                      <td align="left" rowspan="1" colspan="1">Locally advanced</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Age</td>
                      <td align="left" rowspan="1" colspan="1">Median (range): 65 years</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Number of prior systemic therapies</td>
                      <td align="left" rowspan="1" colspan="1">0</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Performance status: ECOG</td>
                      <td align="left" rowspan="1" colspan="1">0â20<break/>1â31<break/>2â0<break/>3â0<break/>Unknownâ0</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Cancer types or histologic subtypes</td>
                      <td align="left" rowspan="1" colspan="1">Adenocarcinoma of pancreas, 51</td>
                    </tr>
                  </tbody>
                </table>
              </table-wrap>
            </sec>
            <sec id="s5">
              <title>Primary Assessment Method</title>
              <table-wrap position="float" id="T1004">
                <table frame="hsides" rules="groups" width="100%" border="1">
                  <colgroup span="1">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                  </colgroup>
                  <thead>
                    <tr>
                      <th align="left" rowspan="1" colspan="1">Title</th>
                      <th align="left" rowspan="1" colspan="1">12-month survival</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Number of patients screened</td>
                      <td align="left" rowspan="1" colspan="1">52</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Number of patients enrolled</td>
                      <td align="left" rowspan="1" colspan="1">52</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Number of patients evaluable for toxicity</td>
                      <td align="left" rowspan="1" colspan="1">51</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Number of patients evaluated for efficacy</td>
                      <td align="left" rowspan="1" colspan="1">51</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Evaluation method</td>
                      <td align="left" rowspan="1" colspan="1">RECIST 1.0</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Response assessment CR</td>
                      <td align="left" rowspan="1" colspan="1"><italic toggle="yes">n</italic> = 1</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Response assessment PR</td>
                      <td align="left" rowspan="1" colspan="1"><italic toggle="yes">n</italic> = 2</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Response assessment SD</td>
                      <td align="left" rowspan="1" colspan="1"><italic toggle="yes">n</italic> = 35</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Response assessment PD</td>
                      <td align="left" rowspan="1" colspan="1"><italic toggle="yes">n</italic> = 13</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">(Median) duration assessments PFS</td>
                      <td align="left" rowspan="1" colspan="1">7.4 months, CI: 4.5-8.6</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">(Median) duration assessments OS</td>
                      <td align="left" rowspan="1" colspan="1">12.1 months, CI: 7.9-15.9</td>
                    </tr>
                  </tbody>
                </table>
                <table frame="hsides" rules="groups" width="100%" border="1">
                  <thead>
                    <tr>
                      <th align="left" rowspan="1" colspan="1">Outcome notes</th>
                      <th align="left" rowspan="1" colspan="1"/>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">12-month survival</td>
                      <td align="left" rowspan="1" colspan="1">50% (95% CI 38%-67%)</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Median OS</td>
                      <td align="left" rowspan="1" colspan="1">12.1 months (95% CI 7.9-15.9; <xref rid="F1" ref-type="fig">Fig. 1</xref>)</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Median PFS</td>
                      <td align="left" rowspan="1" colspan="1">7.4 months (95% CI 4.5-8.6; <xref rid="F2" ref-type="fig">Fig. 2</xref>)</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Confirmed response:</td>
                      <td align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Overall response</td>
                      <td align="left" rowspan="1" colspan="1">3/51 (5.9%; 95% CI: 1.2-16.2%) (1 CR, 2 PR)</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Stable disease</td>
                      <td align="left" rowspan="1" colspan="1">35/51 (68.6%)</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Progressive disease</td>
                      <td align="left" rowspan="1" colspan="1">13/51 (25.5%)</td>
                    </tr>
                  </tbody>
                </table>
              </table-wrap>
              <fig position="float" id="F1">
                <label>Figure 1.</label>
                <caption>
                  <p>Overall survival.</p>
                </caption>
                <graphic xlink:href="oyac002f0001" position="float"/>
              </fig>
              <fig position="float" id="F2">
                <label>Figure 2.</label>
                <caption>
                  <p>Progression-free survival.</p>
                </caption>
                <graphic xlink:href="oyac002f0002" position="float"/>
              </fig>
              <table-wrap position="float" id="T1005">
                <table frame="hsides" rules="groups" width="100%" border="1">
                  <colgroup span="1">
                    <col align="left" span="1"/>
                  </colgroup>
                  <thead>
                    <tr>
                      <th align="left" rowspan="1" colspan="1">Adverse Events</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"><xref rid="T1" ref-type="table">Table 1</xref> shows adverse events of grade 3 or higher that were at least possibly related to treatment.</td>
                    </tr>
                  </tbody>
                </table>
              </table-wrap>
            </sec>
            <sec id="s6">
              <title>Assessment, Analysis, and Discussion</title>
              <table-wrap position="float" id="T1006">
                <table frame="hsides" rules="groups" width="100%" border="1">
                  <colgroup span="1">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                  </colgroup>
                  <tbody>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Completion</td>
                      <td align="left" rowspan="1" colspan="1">Study Completed</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Investigatorâs Assessment</td>
                      <td align="left" rowspan="1" colspan="1">Poorly tolerated/not feasible</td>
                    </tr>
                  </tbody>
                </table>
              </table-wrap>
              <p>The prognosis of patients with locally advanced adenocarcinoma of the pancreas remains poor, and long-term survivors are rare.<sup><xref rid="CIT0001" ref-type="bibr">1</xref></sup> Current treatment guidelines recommend upfront cytotoxic chemotherapy for patients with adequate performance status, typically a multi-agent regimen such as either FOLFIRINOX or gemcitabine with nab-paclitaxel.<sup><xref rid="CIT0001" ref-type="bibr">1</xref>,<xref rid="CIT0003" ref-type="bibr">3</xref>,<xref rid="CIT0004" ref-type="bibr">4</xref></sup> External beam radiotherapy or stereotactic body radiation therapy (SBRT) is commonly used after initial 4-6 months of systemic therapy assuming disease stability or an objective response, but the contribution of additional radiotherapy, including its effect on survival, remains unclear.<sup><xref rid="CIT0005" ref-type="bibr">5</xref>,<xref rid="CIT0006" ref-type="bibr">6</xref></sup> In this trial, the radiation consisted of 50.4 Gy in 28 fractions using 3-dimensional treatment planning, as was the standard at the time of conducting this trial. In fact, available evidence suggests that there is little if any survival advantage of including radiotherapy following chemotherapy.<sup><xref rid="CIT0002" ref-type="bibr">2</xref></sup> In patients who either have a partial response or stable disease after 4-6 months of systemic therapy, concurrent chemoradiotherapy followed by a period of observation is not unreasonable and is supported as an option for patients who do not develop metastatic disease while on initial chemotherapy in the most recent National Comprehensive Cancer Network (NCCN) guidelines.<sup><xref rid="CIT0004" ref-type="bibr">4</xref></sup></p>
              <p>Patients with locally advanced pancreatic adenocarcinoma should be evaluated by a multidisciplinary team at a large-volume center with substantial experience treating patients with this entity. Carefully selected patients with locally advanced tumors may be considered for aggressive upfront therapy with an eventual goal of resection. Neoadjuvant chemotherapy, typically with FOLFIRINOX, followed by chemoradiotherapy may result in sufficient downstaging for resection, often with complex vascular resections. Although not considered standard therapy, experience from single centers suggests that receipt of neoadjuvant chemotherapy, normalization of previously elevated CA 19-9 and pathological response is associated with more favorable outcomes, but prospective data are lacking.<sup><xref rid="CIT0007" ref-type="bibr">7-10</xref></sup></p>
              <p>The EGFR pathway has been suggested as a potential target for systemic therapy in patients with pancreatic adenocarcinoma. Increased expression of EGFR has been associated with worse outcomes, but the incorporation of EGFR-directed therapy has yielded minimal improvement in survival and inclusion of EGFR-directed drugs is not recommended outside of clinical trials.<sup><xref rid="CIT0011" ref-type="bibr">11-13</xref></sup> Based on the available evidence, EGFR-directed therapy is very unlikely to meaningfully improve outcomes of patients with advanced pancreatic adenocarcinoma.</p>
              <p>The approach in the currently reported trial cannot be recommended for clinical practice for several reasons. Firstly, the studied regimen was associated with substantial toxicities, well in excess of what is seen with conventional systemic therapy. Secondly, EGFR-directed therapy has not been shown to improve outcomes such as PFS and OS and the survival outcomes of this study compare unfavorably with other trials done in similar patient populations. Thirdly, there has been a paradigm change with regard to the management of locally advanced adenocarcinoma of the pancreas over recent years. Upfront chemoradiotherapy is no longer recommended but can be considered after an initial phase of systemic therapy in cases where no metastases have developed. For those reasons, the approach reported in this trial is not recommended for further study or for clinical practice.</p>
            </sec>
          </body>
          <back>
            <ack id="a1">
              <title>Acknowledgments</title>
              <p>This trial was sponsored by the Alliance for Clinical Trials in Oncology. The following institutional networks participated in the study: Ascension via Christi Hospitals Wichita, Wichita, KS, Shaker Dakhil; Big Sky Oncology, Cancer Research Consortium of West Michigan NCORP, Grand Rapids, MI, Kathleen Yost, UG1CA189971; Cancer Research for the Ozarks NCORP, Springfield, MO, Jay Carlson, UG1CA189822; Cancer Research of Wisconsin and Northern Michigan Consortium, Green Bay, WI, Anthony Jaslowski; Carle Cancer Center NCI Community Oncology Research Program, Urbana, IL, Kendrith Rowland, UG1CA189861; Catholic Health Initiatives NCORP, Englewood, CO, Richard Deming; Colorado Cancer Research Program CCOP; Dayton NCI Community Oncology Research Program, Dayton, OH, Howard Gross, UG1CA189957; Essentia Health NCI Community Oncology Research Program, Duluth, MN, Bret Friday, UG1CA189812; Heartland Cancer Research NCORP, Decatur, IL, Bryan Faller, UG1CA189830; Iowa-Wide Oncology Research Coalition NCORP, Des Moines, IA, Robert Behrens, UG1CA189816; Mayo Clinic LAPS, Rochester, MN, Steven Alberts, UG1CA232760; Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, MN, Daniel Anderson, UG1CA189863; Michigan Cancer Research Consortium NCORP, Ann Arbor, MI, Philip Stella, UG1CA189971; Pacific Cancer Research Consortium NCORP, Seattle, WA, Alison Conlin, UG1CA189953; Sanford NCI Community Oncology Research Program of the North Central Plains, Sioux Falls, SD, Preston Steen, UG1CA189825; and Western States Cancer Research NCORP, Denver, CO, Nicholas DiBella, UG1CA189805.</p>
            </ack>
            <sec id="s150">
              <title>Conflict of Interest</title>
              <p>The authors indicated no financial relationships.</p>
            </sec>
            <sec sec-type="data-availability" id="s151">
              <title>Data Availability</title>
              <p>The data underlying this article will be shared on reasonable request to the corresponding author.</p>
            </sec>
            <ref-list id="r1">
              <title>References</title>
              <ref id="CIT0001">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Balaban</surname><given-names>EP</given-names></string-name>, <string-name><surname>Mangu</surname><given-names>PB</given-names></string-name>, <string-name><surname>Khorana</surname><given-names>AA</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline.</article-title><source>J Clin Oncol.</source><year>2016</year>;<volume>34</volume>(<issue>22</issue>):<fpage>2654</fpage>-<lpage>2668</lpage>.<pub-id pub-id-type="pmid">27247216</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0002">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hammel</surname><given-names>P</given-names></string-name>, <string-name><surname>Huguet</surname><given-names>F</given-names></string-name>, <string-name><surname>van Laethem</surname><given-names>JL</given-names></string-name>, <etal>et al.</etal></person-group>; <collab>LAP07 Trial Group.</collab><article-title>Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial.</article-title><source>JAMA.</source><year>2016</year>;<volume>315</volume>(<issue>17</issue>):<fpage>1844</fpage>-<lpage>1853</lpage>.<pub-id pub-id-type="pmid">27139057</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0003">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ducreux</surname><given-names>M</given-names></string-name>, <string-name><surname>Cuhna</surname><given-names>AS</given-names></string-name>, <string-name><surname>Caramella</surname><given-names>C</given-names></string-name>, <etal>et al.</etal></person-group><collab>ESMO Guidelines Committee.</collab><article-title>Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.</article-title><source>Ann Oncol.</source><year>2015</year>;<volume>26</volume>(<issue>Suppl 5</issue>):<fpage>v56</fpage>-<lpage>v68</lpage>.<pub-id pub-id-type="pmid">26314780</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0004">
                <label>4.</label>
                <mixed-citation publication-type="other"><collab>Pancreatic Adenocarcinoma.</collab><comment>NCCN guidelines version 1.2020</comment> (accessed <comment>10/19/2020</comment>). <year>2020</year>.</mixed-citation>
              </ref>
              <ref id="CIT0005">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huguet</surname><given-names>F</given-names></string-name>, <string-name><surname>AndrÃ©</surname><given-names>T</given-names></string-name>, <string-name><surname>Hammel</surname><given-names>P</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.</article-title><source>J Clin Oncol.</source><year>2007</year>;<volume>25</volume>(<issue>3</issue>):<fpage>326</fpage>-<lpage>331</lpage>.<pub-id pub-id-type="pmid">17235048</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0006">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sultana</surname><given-names>A</given-names></string-name>, <string-name><surname>Tudur Smith</surname><given-names>C</given-names></string-name>, <string-name><surname>Cunningham</surname><given-names>D</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy.</article-title><source>Br J Cancer.</source><year>2007</year>;<volume>96</volume>(<issue>8</issue>):<fpage>1183</fpage>-<lpage>1190</lpage>.<pub-id pub-id-type="pmid">17406358</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0007">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Truty</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Kendrick</surname><given-names>ML</given-names></string-name>, <string-name><surname>Nagorney</surname><given-names>DM</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer.</article-title><source>Ann Surg</source><year>2019</year>.</mixed-citation>
              </ref>
              <ref id="CIT0008">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gemenetzis</surname><given-names>G</given-names></string-name>, <string-name><surname>Groot</surname><given-names>VP</given-names></string-name>, <string-name><surname>Blair</surname><given-names>AB</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection.</article-title><source>Ann Surg.</source><year>2019</year>;<volume>270</volume>(<issue>2</issue>):<fpage>340</fpage>-<lpage>347</lpage>.<pub-id pub-id-type="pmid">29596120</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0009">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Perri</surname><given-names>G</given-names></string-name>, <string-name><surname>Prakash</surname><given-names>L</given-names></string-name>, <string-name><surname>Qiao</surname><given-names>W</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Response and survival associated with first-line FOLFIRINOX vs gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma.</article-title><source>JAMA Surg.</source><year>2020</year>;<volume>155</volume>(<issue>9</issue>):<fpage>832</fpage>-<lpage>839</lpage>.<pub-id pub-id-type="pmid">32667641</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0010">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pietrasz</surname><given-names>D</given-names></string-name>, <string-name><surname>Turrini</surname><given-names>O</given-names></string-name>, <string-name><surname>Vendrely</surname><given-names>V</given-names></string-name>, <etal>et al.</etal></person-group><article-title>How does chemoradiotherapy following induction FOLFIRINOX improve the results in resected borderline or locally advanced pancreatic adenocarcinoma? an AGEO-FRENCH multicentric cohort.</article-title><source>Ann Surg Oncol.</source><year>2019</year>;<volume>26</volume>(<issue>1</issue>):<fpage>109</fpage>-<lpage>117</lpage>.<pub-id pub-id-type="pmid">30362063</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0011">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Korc</surname><given-names>M</given-names></string-name>, <string-name><surname>Chandrasekar</surname><given-names>B</given-names></string-name>, <string-name><surname>Yamanaka</surname><given-names>Y</given-names></string-name>, <string-name><surname>Friess</surname><given-names>H</given-names></string-name>, <string-name><surname>Buchier</surname><given-names>M</given-names></string-name>, <string-name><surname>Beger</surname><given-names>HG.</given-names></string-name></person-group><article-title>Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha.</article-title><source>J Clin Invest.</source><year>1992</year>;<volume>90</volume>(<issue>4</issue>):<fpage>1352</fpage>-<lpage>1360</lpage>.<pub-id pub-id-type="pmid">1401070</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0012">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moore</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Goldstein</surname><given-names>D</given-names></string-name>, <string-name><surname>Hamm</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>; <collab>National Cancer Institute of Canada Clinical Trials Group.</collab><article-title>Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of canada clinical trials group.</article-title><source>J Clin Oncol.</source><year>2007</year>;<volume>25</volume>(<issue>15</issue>):<fpage>1960</fpage>-<lpage>1966</lpage>.<pub-id pub-id-type="pmid">17452677</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0013">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Philip</surname><given-names>PA</given-names></string-name>, <string-name><surname>Benedetti</surname><given-names>J</given-names></string-name>, <string-name><surname>Corless</surname><given-names>CL</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest oncology group-directed intergroup trial S0205.</article-title><source>J Clin Oncol.</source><year>2010</year>;<volume>28</volume>(<issue>22</issue>):<fpage>3605</fpage>-<lpage>3610</lpage>.<pub-id pub-id-type="pmid">20606093</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
